Subjects were administered single doses of 0, 250 and 500 μg/kg THC by smoking.
In each period, according to the randomization scheme, subjects were administered a single 0.5 mg oral dose of either the Test or Reference products.
As part of common practice in clinical studies with opioids, subjects were administered 50 mg naltrexone hydrochloride (tablet), an opioid antagonist, before and after treatment.
Four subjects were administered multiple 6 mg equivalent doses of ISIS-SMNRx and up to 16 subjects will be administered multiple 12 mg equivalent doses.
During a randomized trial where subjects were administered three preparations of A. sativum versus placebo it was observed that A. sativum did not significantly alter LDL-cholesterol, HDL-cholesterol, triglycerides, or total cholesterol-HDL ratio [53].
The administration time is under 5 min. In an initial validation study of this scale, 100 human subjects were administered the KMSK scale concurrently with the Structured Clinical Interview for DSM-IV (SCID-I DSM-IV version).
In a double-blind placebo-controlled randomized cross-over full factorial design, 27 healthy subjects were administered aroma profiles by a computer-controlled stimulator based on air dilution olfactometry.
In a randomized, double-blind, placebo-controlled parallel design (n = 10/group), 40 subjects were administered a single high-fat meal with either a placebo or 1 of 3 Asiatic plantain extract beverages (low, intermediate, or high dose).
Prior to testing on each day, subjects were administered either nicotine (4 mg) or placebo lozenges, in a between-subjects, four-group, 2 × 2 design (nicotine or placebo on days 1 and 2).
Measurements were performed before, during and after a hypnotic session during which the subjects were administered a French adaptation of the Stanford Hypnotic Susceptibility Scale and then standardized suggestions of analgesia limited to the left foot.
All subjects were administered the seven tasks in a different order.
